Agilon Health (NYSE:AGL) Price Target Raised to $85.00

Agilon Health (NYSE:AGL) had its target price lifted by JPMorgan Chase & Co. from $31.00 to $85.00 in a report issued on Monday morning,Benzinga reports. The firm currently has an underweight rating on the stock.

Other equities research analysts have also issued research reports about the company. Barclays set a $111.00 price target on Agilon Health and gave the company an “equal weight” rating in a research report on Thursday, August 6th. Citigroup upgraded Agilon Health from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $105.00 to $115.00 in a research report on Monday, August 10th. TD Cowen reaffirmed a “hold” rating and issued a $55.00 price objective (up from $17.00) on shares of Agilon Health in a research note on Monday, May 11th. Deutsche Bank Aktiengesellschaft upgraded Agilon Health from a “hold” rating to a “buy” rating and upped their target price for the company from $33.00 to $49.00 in a report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $97.70.

Agilon Health Price Performance

Shares of NYSE:AGL opened at $95.19 on Monday. The firm has a market cap of $1.60 billion, a PE ratio of -6.67 and a beta of 3.01. The firm’s fifty day moving average is $104.90 and its 200-day moving average is $62.80. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.08 and a current ratio of 1.08. Agilon Health has a 52 week low of $7.48 and a 52 week high of $133.04.

Agilon Health (NYSE:AGL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.90. The company had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Agilon Health had a negative net margin of 3.92% and a negative return on equity of 119.38%. Sell-side analysts predict that Agilon Health will post -2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Proficio Capital Partners LLC purchased a new position in shares of Agilon Health during the 2nd quarter valued at $210,000. Bank of New York Mellon Corp increased its holdings in Agilon Health by 9.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock worth $3,787,000 after acquiring an additional 3,074 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in Agilon Health in the 2nd quarter worth about $702,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Agilon Health by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock valued at $927,000 after acquiring an additional 7,209 shares during the period. Finally, Dynamic Technology Lab Private Ltd raised its stake in Agilon Health by 28.4% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after acquiring an additional 10,424 shares during the period.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.